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Abstract:Cutaneous diabetic wounds greatly afect the quality of
life of patients, causing a substantial economic impact on the
healthcare system. The limited clinical success of conventional
treatments is mainly atributed to the lack of knowledge of the
pathogenic mechanisms related to chronic ulceration. Therefore,
management of diabetic ulcers remains a chalenging clinical issue.
Within this context, reliable animal models that recapitulate
situations of impaired wound healing have become essential. In this
study, we established a newin vivohumanised model of delayed
wound healing in a diabetic context that reproduces the main
features of the human disease. Diabetes was induced by multiple
low doses of streptozotocin in bioengineered human skin engrafted
immunodeficient mice. The significant delay in wound closure
exhibited in diabetic wounds was mainly atributed to alterations in
the granulation tissue formation and resolution, involving defects
in wound bed maturation, vascularisation, inflammatory response
and colagen deposition. In the new model, a cel based wound
therapy consisting of the application of plasma derived fibrin
dermal scafolds containing fibroblasts consistently improved the
healing response by triggering granulation tissue maturation and
further providing a suitable matrix for migrating keratinocytes
during wound re epithelialisation. The present preclinical wound
healing model was able to shed light on the biological processes
responsible for the improvement achieved, and these findings can
be extended for designing new therapeutic approaches with clinical
relevance.
Key words:animal models – delayed wound healing – diabetic wounds –
fibroblasts – tissue engineering
Introduction
Tissue repair is accomplished by the close coordination of the
processes of inflammation, re epithelialisation, granulation tissue
formation and dermal remodeling that overlap in space and time
(1 3). Chronic non healing wounds, such as diabetic ulcers, fail to
proceed through these sequential events (4), leading to diminished
quality of life, frequent hospitalisation and increased morbidity
and mortality (5,6). Moreover, this pathologic healing condition
causes significant socio economic consequences for patients, their
families and the healthcare system (7).
A peripheral nerve dysfunction induced by sustained hyper
glycaemia, with or without coexisting ischaemia, combined with
repeated minor trauma seem to be the prime causes of diabetic
skin ulcers (8 10). In conjunction with the diabetic neuropathy,
several altered celular and molecular processes, mainly related to
granulation tissue formation and resolution, have been linked to
impaired diabetic cutaneous wound healing (11).
Due to the limited understanding of the mechanisms responsi
ble for poor healing, conventional therapies are unable to guaran
tee an adequate and sustained regeneration of the damaged tissue
(12). More recently, fibroblasts administered as a part of bioengi
neered dermal or dermo epidermal substitutes ofer new therapeu
tic possibilities in both animal models and clinical studies
(13 15). In particular, fibroblasts are able to grow and provide
multiple growth factors and extracelular matrix proteins (16 18)
that might be altered in diabetic wound beds. Consequently,
tissue engineering approaches are emerging as smart strategies for
the treatment of chronic cutaneous wounds such as diabetic
ulcers (19).
The study of diabetic wound healing in patients is limited by
obvious ethical considerations and the heterogeneity of the
disease. Thus, apart from a few studies performed on volunteers
(20 22), current knowledge of wound healing mainly stems from
the use of a broad variety of transgenic and mutant murine
models (23 26). Despite the unquestionable value of murine
models, innovative approaches must been explored in a human
ised context to obtain results of clinical relevance. To this end,
chimeric systems composed of skin of human origin, vascularised
by murine vessels, have been exploited by several groups, includ
ing ours (27 29). The skin humanised mouse model developed
by our laboratory is based on the permanent engraftment of a
fibrin based bioengineered human skin onto the back of
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immunodeficient mice (29,30). The orthotopic bioengineered
skin transplantation methodology enables the generation of
numerous mice engrafted with a significant homogeneous area of
single donor derived stable human skin (31,32) and ofers
multiple possibilities to faithfuly recreate diverse cutaneous
pathological (33 35) and physiological processes (36,37).
In the present work, we report a newin vivomodel of delayed
wound healing in a diabetic context using the skin humanised
mouse model that resembles a clinicaly meaningful skin repair
deficient condition. Furthermore, the model has been used as a
preclinical platform to evaluate the efectiveness of fibroblast
containing fibrin based dermal matrices which considerably
enhanced tissue repair.
Methods
Primary culture of human keratinocytes and fibroblasts
Cels from skin biopsies of three healthy donors were isolated by
mechanical and enzymatic digestion as previously described
(30,38,39). Donors were subjected to standard serological tests
according to national regulations (RD 1301/2006). Donors gave
their writen informed consent for biopsies, and al experimental
procedures were conducted in accordance with the World Medical
Association Declaration of Helsinki and subsequent revisions.
Grafting of bioengineered human skin equivalents: the skin
humanised mice
Six week old female immunodeficient nude mice (Rj: NMRI
Foxn1nu; Elevage Janvier, Le Genest Saint Isle, France) were
orthotopicaly grafted with bioengineered cutaneous equivalents.
This seting contains human keratinocytes (epidermal component)
seeded on a plasma derived fibrin matrix populated with live
human fibroblasts (dermal component). Grafting was performed
as previously described (29,30) under sterile conditions at the
CIEMAT Laboratory Animals Facility (European registration num
ber ES280790000183; Spanish registration number 28079 21 A).
Al handling was carried out according to European and Spanish
laws and regulations on the protection and use of animals in
scientific research. Experimental procedures were approved by the
Animal Experimentation Ethical Commitee of CIEMAT.
Wound healing experimental design in the diabetic skin
humanised mouse model
Diabetes was induced in skin humanised mice at 10 weeks post
grafting by intraperitoneal injections of streptozotocin (STZ;
Sigma Aldrich, St. Luis, MO, USA), dissolved in sodium citrate
bufer (0.01M; pH 4.5). Blood glucose levels were routinely mea
sured under non fasted conditions by tail vein sampling using an
Accu Check Blood Glucose Monitor (Roche Diagnostic, Indianap
olis, IN, USA). Mice whose blood glucose levels exceeded 250 mg/
dl on two consecutive measurements separated by an interval of
48 h were considered diabetic. Normoglycaemic mice were used as
controls.
Sustained release bovine insulin pelets (Linbit, LinShin, North
Scarborough, ON, Canada) were provided to severely diabetic
mice (blood glucose levels higher than 500 mg/dl) to make hyper
glycaemia compatible with life. Further information is provided in
Fig. S1.
Ful thickness 2 mm excisional wounds were created in the sta
ble human skin graft using a biopsy punch (Pfm Medical Ag.,
Cologne, Germany). Circular excisioned tissue was harvested and
used as a reference for anatomopathological analysis. Clinical
folow up of the healing process was performed by using a camera
coupled to a stereomicroscope (Olympus, Barcelona, Spain).
Anatomopathological analysis was performed at three (n=4
mice per experimental group), seven (n=10) and 14 days
(n=3) postwounding. Sample harvesting and processing were
carried out as previously described (36,40). Serial 4lm cross sec
tions were obtained. The whole sample was sectioned to determine
the centre of the wound and adequately monitor the healing pro
cess. Haematoxylin and eosin staining (Thermo Shandon GmbH,
Darmstadt, Germany) was routinely performed in tissue sections.
Wound healing analysis
The re epithelialisation percentage was calculated by the formula:
1009 [(wound diameter epidermal gap)/wound diameter] (41).
Immunohistochemical and immunofluorescence procedures were
performed in tissue sections adjacent to the centre folowing stan
dard protocols.
To determine the human origin of epidermal and dermal cels,
species specific antibodies against involucrin (dilution 1:100; clone
SY5 mAb, Sigma, St Louis, MO, USA) and vimentin (dilution
1:50; clone V9 mAb, BioGenex, San Ramon, CA, USA) were used,
respectively.
Mature blood vessel density was determined using an antibody
specific forasmooth muscle actin (SMA; dilution 1:400; clone
1A4 mAb; Sigma).
Polymorphonuclear neutrophil (PMN) infiltration in the
wound bed was determined by labeling myeloperoxidase activity
(MPO; dilution 1:50; Hycult Biotechnology, Uden, the Nether
lands).
The nuclear antigen Ki67 (Thermo Scientific, Fremont, CA,
USA) was selected as a cel proliferation marker. In addition, an
antibody against keratin K10 (dilution 1:1000; Covance, Emeryvile,
CA, USA) was used as an early diferentiation marker of keratino
cytes. For Ki67 and keratin K10 staining, a heat induced epitope
retrieval treatment using 10 mMcitrate bufer was required.
Specific biotinylated secondary antibodies were purchased from
Jackson ImmunoResearch Laboratories (West Grove, PA, USA).
After colour development (Avidin Biotin Complex Vectastain Elite
kit; Vector Laboratories, Inc., Burlingame, CA, USA), sections
were counterstained with haematoxylin.
Nerve fibres were visualised by immunofluorescence using an
antibody against the pan neuronal marker protein gene product
9.5 (PGP 9.5; dilution 1:500; ABD Serotec, Oxford, UK) and a
FITC conjugated secondary antibody (Jackson Immuno Research
Laboratories). Cel nuclei were stained with DAPI (Merck,
Darmstadt, Germany). Microphotographs were taken using a flu
orescence microscope (Axioplan 2; Carl Zeiss GmbH, Jena, Ger
many).
Colagen deposition was assessed by picrosirius red staining
folowing standard procedures (42), and stained sections were
analysed by polarised light microscopy (U ANT filter; Olympus).
Treatment of diabetic wounds with bioengineered dermal
equivalents in the skin humanised mouse model
Fibrin based bioengineered dermis containing 106 live human
fibroblasts were applied covering diabetic wounds (n=4) and
were kept in place using TegadermTM
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(3M Health Care, ST Paul,
MN, USA), as previously described (40). After 7 days, wound
samples were colected and analysed. An identical number of
diabetic wounds were treated with acelular fibrin gels.
Statistical analysis
Wound healing parameters were analysed in the diferent experi
mental groups, and means were compared using the two tailed
unpaired Student’sttest. Diferences were considered statisticaly
significant whenP<0.05. Al values were expressed as the
mean SD.
Results
Establishment of a diabetic skin humanised mouse model
Skin humanised mice were treated with STZ, a drug that selec
tively destroysbpancreatic cels (43). Diabetes was induced
10 weeks after grafting, an adequate time period to achieve both
epidermal maturation and complete fibrin remodeling to colage
nous dermis in the regenerated interfolicular human skin
(29,30,32). Within the folowing 2 weeks, 85% of mice receiving
STZ developed hyperglycaemia (250 600 mg/dl) and displayed
polyuria, polyphagia and polydipsia, classical clinical symptoms of
diabetes. As the survival of mice with hyperglycaemic levels over
500 mg/dl was compromised, exogenous insulin was administered
by subcutaneous bioerodible implants and dose was adjusted by
applying one or two microimplants (Fig. S1A).
In this way, a chemicaly induced diabetic skin humanised
mouse model was established, and mature human skin perma
nently engrafted on immunodeficient mice was exposed to
sustained hyperglycaemia for 6 weeks (Fig. 1a). At this time,
histological evidence of pancreatic damage was evidenced (Fig.
S1B D). Moreover, the main cutaneous features reported in
diabetic patients were faithfuly recreated in thisin vivomodel,
although a normal regenerated human skin in terms of epidermal
phenotype and colagenous dermal matrix was observed (Fig. 1b).
Specificaly, a striking reduction of both blood vessels and nerve
fibres depicted by SMA and PGP 9.5 immunostaining was consis
tently displayed in al diabetic animals (Fig. 1c,d). In addition,
SMA positive vessels appeared disorganised, scatered and located
at the reticular dermis in the skin of diabetic animals while vessels
were mainly found in the subepidermal vascular plexus in control
mice (Fig. 1c).
Delayed wound healing response in the diabetic skin
humanised mice
Healing studies were performed by creating ful thickness 2 mm
excisional wounds on the mature stably regenerated human skin of
hyperglycaemic mice. Samples were harvested at 3, 7 and 14 days
postwounding. Although the diabetic healing process was delayed at
al the studied time points, the maximum diferences in the rate of
re epithelialisation were detected at seven after injury (Fig. S2).
Therefore, al the studies were performed at that time point.
The human origin of both keratinocytes involved in re epitheli
alisation and fibroblasts responsible for dermal matrix remodeling
after excisional wounding was certified (Fig. S3).
Experimental diabetes distressed the progression of the healing
process, leading to a statisticaly significant reduction of the
re epithelialisation rate in 7 day wounds (Fig. 2a c). Indeed, only
12% of the wound was re epithelialised in hyperglycaemic animals
compared to 47% in controls.
Biological alterations underlying delayed wound healing in
the diabetic skin humanised mice
A representative panel of parameters was evaluated to investigate
the alterations underlying diabetes wound repair impairment in
the model developed herein.
Streptozotocin treated animals exhibited impaired formation
and maturation of the granulation tissue. Thereby, picrosirius red
staining in 7 day control wounds showed a colagen rich wound
bed, whilst a sparse colagen deposition was noticeable in the dia
betic wound beds (Fig. 2d). Consistent with poor dermal matrix
remodeling, a significant detrimental change in vascular density
within the granulation tissue was detected in diabetic wounds
(Fig. 3a,b). This impaired angiogenic response conceivably
reflected the defective cutaneous vascularisation observed in
diabetic skin humanised mice (Fig. 1c).
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Figure 1.Reduced cutaneous vascularisation and innervation in the regenerated
human skin of diabetic mice. (a) Schematic representation of the streptozotocin
induced diabetes experimental protocol. Diabetes was induced at 10 weeks
postgrafting, after both epidermal maturation and dermal remodeling were
completed in the regenerated human skin. STZ was administered on five consecutive
days (four doses of 50 mg/kg folowed by a single dose of 100 mg/kg). (b) Picrosirius
red staining. A normal colagenous dermal matrix was found in diabetic mice after
6 weeks of STZ administration. Scale bar=100lm. (c) SMA immunoperoxidase
staining. Mature blood vessel density was substantialy reduced in the STZ treated
mice. Scale bar=75lm. (d) PGP 9.5 immunofluorescence. Considerable qualitative
changes in cutaneous innervation were detected in STZ treated mice. Scale
bar=50lm. Experiments were performed with 10 mice in each group. In panels B,
C and D, dermo epidermal boundaries are outlined by dashed lines. Abbreviations:
wks, weeks; STZ, streptozotocin; SMA,a
3
smooth muscle actin; PGP 9.5, protein
gene product 9.5.
The inflammatory response in the stroma of 7 day diabetic
wounds was associated with a massive infiltration of myeloperoxi
dase positive neutrophils flanking the fibrin plug (Fig. 3c). In con
trast, much fewer neutrophils were found in the granulation tissue
of control wounds, revealing a practicaly resolved inflammatory
phase.
The Ki67 proliferative index of basal keratinocytes was asessed in
unwounded and wounded regenerated human skin. Surprisingly, on
day 7, a comparable postwounding proliferative burst was observed in
both experimental groups (Fig. 3d,e). However, while wel developed
migratory tongues, with no stratum corneum and decreasing expres
sion of K10, were observed in controls, diabetic wounds exhibited a
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Figure 2.Impaired granulation tissue formation and dermal remodeling
contributed to delayed wound healing in the diabetic skin humanised mouse
model. (a) Percentage of re epithelialisation calculated by the formula: 1009
[(wound diameter epidermal gap)/wound diameter]. Values are expressed as
mean SD (n=10 mice in each group).**P<0.01. A statisticaly significant
reduction of re epithelialisation percentage was associated with hyperglycaemia.
(b) Composite pictures of H&E stained 7 day wounds. Diminished wound
re epithelialisation was evidenced by a larger epidermal gap distance as indicated
by double arowhead. Scale bar=300lm. (c) Representative photographs of
excisional wounds at 7 days postwounding. Scale bar=1 mm. (d) Colagen
deposition analysed by picrosirius red staining. Panoramic view (scale
bar=250lm) and close up view (scale bar=100lm)of the centre of 7 day
wounds. Note the sparse colagen deposition in the 7 day diabetic wound beds
while bi refringent colagen type I fibres (orange yelow colour) were predominantly
observed in the granulation tissue of control wounds. Colagen type II (green
colour) was also distinguishable in 7 day control wounds. Dashed black lines show
the migratory tongues at the wound margins in panels B and D. Abbreviations:
H&E, haematoxylin and eosin.
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Figure 3.Reduced vascularisation and persistent neutrophil infiltration without
epidermal proliferation alteration in diabetic wounds. (a) Quantitative analysis of
SMA positive vessels. Four randomly chosen high power fields were counted per
wound. Results (mean SD) are from 10 mice in each group.**P<0.01.
(b) SMA immunoperoxidase staining in the granulation tissue of 7 day control and
diabetic wounds. Scale bar=50lm. (c) Immunodetection of MPO positive
polymorphonuclear neutrophils in areas surounding the granulation tissue at
7 days after injury. Scale bar=50lm. (d) Ki67 quantitative analysis in unwounded
skin and in the neo epidermis of 7 day wounds. A total of 300 nuclei were
counted, and the proliferation index was calculated as the percentage of Ki67
positive nuclei in relation to the total number of nuclei of the basal keratinocyte
layer. Results are expressed as mean SD. (e) Ki67 staining of 7 day wounds.
Scale bar=100lm. (f) Immunoperoxidase staining of keratin K10. Scale
bar=50lm. In panels E and F, dermo epidermal boundaries are outlined by
dashed black lines. Abbreviations: SMA,a
4
smooth muscle actin; MPO,
myeloperoxidase; ns, non significant.
fuly keratinised acanthotic epithelium with a concomitant expression
of keratin K10 reaching the edge of the wound (Fig. 3e, f), evidencing
impaired migratory activity of keratinocytes.
Noticeably, long term analysis revealed that 7 day postwoun
ding defects were stil evident, albeit atenuated, in completely
re epithelialised 14 day diabetic wounds (Fig. S2C).
Bioengineered dermis accelerated wound healing in diabetic
wounds
Diabetic wounds in the skin humanised mouse model displayed
delayed granulation tissue formation with poor vascular and celu
lar density, mimicking the pathological conditions that predispose
diabetic patients to develop cutaneous ulcers (4,44,45). With the
aim of correcting these biological alterations, the therapeutic
potential of tissue engineered dermal equivalents containing
human fibroblasts assembled in a three dimensional fibrin matrix
was evaluated in a diabetic context (Fig. S4). In the preclinical
model, a significant healing improvement was seen in diabetic
wounds at 7 days post treatment (Fig. 4a,b), achieving a
re epithelialisation rate comparable to that found in untreated
control wounds (Fig. 2a). Moreover, a granulation tissue rich in
colagen was observed in diabetic wounds after the treatment with
bioengineered dermal equivalents (Fig. 4c). Additionaly, fibro
blast containing bioengineered dermis seemed to exert an angio
genic efect during granulation tissue formation (Fig. 4d,e), and
indeed, vascular density in treated diabetic wounds was compara
ble to that found in untreated controls (Fig. 3a). Furthermore, no
noticeable efects on granulation tissue formation were detected
when fibroblasts were not included in the fibrin gels used for
wound treatment (Fig. 4c e).
Our results demonstrated, in a preclinical model, the efective
ness of bioengineered dermal equivalents in diabetic wounds,
particularly through the promotion of wound bed maturation.
Discussion
Diabetes afects approximately 2% of the world population in
developed countries and its incidence increases in relation to
current lifestyle (46). Diabetic patients frequently sufer from
impaired wound healing and are consequently prone to develop
cutaneous ulcers with a high rate of recurrence that often become
chronic (5,6,47). The development of efective treatments for heal
ing chronic ulcers largely depends on understanding the patho
genic mechanisms involved. This poses the need for reliable
animal models that recapitulate situations of impaired wound
healing (23,48). The db/db mouse model presents delayed celular
infiltration, granulation tissue formation and colagen deposition,
as wel as prolonged persistence of neutrophils and reduced angio
genesis (24,26). These defects have also been depicted in our
model. However, extrapolation of results coming from rodent and
other smal mammal models should be interpreted with caution,
due to major architectural and functional diferences with human
epidermis (49). In fact, wound healing in mice is a process that
occurs mainly at the expense of contraction, a mechanism of
minor relevance in human skin (40,50). To overcome these
problems, several groups, including ours, have developed a skin
humanised mouse model (28 30,51). Specificaly, the model devel
oped in our laboratory faithfuly reproduces the main features of
human healing at both structural and functional levels (36,40).
Our preclinical humanised wound healing system comprises two
processes of skin regeneration. The first entails the grafting of bio
engineered human skin onto 12 mm excisional wounds in immu
nodeficient mice (29,30). The second regeneration process
involves the closure of 2 mm smal ful thickness wounds per
formed in mature, quiescent and stably engrafted human skin
(10 12 weeks after grafting). Closure of these smal wounds is
carried out by human keratinocytes and human fibroblasts with
minimal contraction contributing to wound resolution (40).
To establish a model of wound healing impairment in the skin
humanised mouse model, a pharmacological induced diabetes
protocol based on STZ administration was employed. Both sur
vival and hyperglycaemia were modulated by a subcutaneous insu
lin implant that guaranteed elevated but life compatible levels of
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Figure 4.Fibroblast containing bioengineered dermis enhanced wound healing in
the diabetic skin humanised mouse model. (a) Representative photographs (scale
bar=1 mm) and composite pictures showing panoramic view of 7 day diabetic
wounds stained with H&E (scale bar=500lm). Accelerated wound closure was
evidenced in diabetic wounds after treatment by a reduction of the epidermal
gap distance (double arowhead). Dashed black lines delimit the wound margins.
(b) Percentage of re epithelialisation in diabetic wounds. Results are expressed as
mean SD (n=4 mice in each group).**P<0.01;*P<0.05. (c) Picrosirius red
staining in centre of 7 day diabetic wounds. A colagen enriched granulation tissue
was observed in diabetic wounds after treatment with bioengineered dermis. Scale
bar=50lm. (d) SMA immunoperoxidase staining in the granulation tissue of
7 day diabetic wounds. A significant increase in the vascular density in diabetic
wounds treated with bioengineered dermis was observed. Scale bar=50lm.
(e) Quantitative analysis of SMA positive blood vessels. Results are expressed as
mean SD.**P<0.01;*P<0.05. Abbreviations: H&E, haematoxylin and eosin;
SMA,a
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smooth muscle actin.
blood glucose during a period of time adequate to cause an
impact on the skin.
Hyperglycaemia induced nerve damage resulting in peripheral
neuropathy is a common complication in diabetes (10). As a
result of metabolic abnormalities, these patients may also present
endothelial dysfunction and alterations in the vascular supply to
organs, including the skin (8,52). Both decreased innervation and
vascularisation were exhibited on the regenerated human skin of
diabetic mice exposed to hyperglycaemia for 6 weeks, proving the
suitability of our protocol. Moreover, the significantly delayed
wound closure in STZ treated mice reproduces the healing
impairment associated with diabetes in patients (4,11) and in
other diabetic animal models (24,26).
Defects associated with granulation tissue formation and their
subsequent resolution seem to be responsible for the delayed heal
ing process in the present model. Specificaly, poorly celularised
7 day diabetic wound beds with reduced colagen deposition
resulted in an inadequate matrix for cel migration. These altera
tions correlate with the defective fibrinolysis and loose extracelu
lar matrix deposition described in diabetic patients (44,53). It has
been proposed that glycation of proteins, such as fibrinogen or
enzymes related to fibrin plug degradation, delays its resolution
and thus adversely afects migration of epithelial tongues in dia
betic wounds (54). In addition, alterations of the subepidermal
vascular plexus of diabetic mice observed prior to wound creation
were further evidenced during the angiogenic response triggered
by the healing stimulus. Thus, inadequately vascularised granula
tion tissue might not provide the metabolic support required for
cel recruitment, hampering the tissue repair process as described
in patients (45) and in other diabetic animal models (26).
In the new diabetic model herein described, a prolonged inflam
matory response, mainly consisting of neutrophils, could be gener
ating a proteolytic and pro oxidant environment in the wound bed,
thus contributing to the delayed healing progress (55). Indeed, a
sustained presence of polymorphonuclear granulocytes has been
reported in patients and animal models of diabetes (56,57).
Controversial data concerning keratinocyte proliferation and
hyperglycaemia have been reported. Although prolonged exposure
to high glucose inhibitsin vitro
6
human keratinocyte proliferation
(58,59), other evidences support that keratinocytes at the chronic
ulcer edge are hyperproliferative (60). In the model described here, a
postinjury keratinocyte proliferation burst without significant difer
ences associated with diabetes was observed. We thus hypothesise
that epithelial cels of the diabetic wound edges were capable of
responding to proliferative signals but epidermal migration might be
compromised because of the immaturity of the wound bed. As a
result, keratinocytes stil expressing markers of diferentiation accu
mulated at the edge of the wound, forming an acanthotic epithelium.
Long term analysis revealed that defects responsible for delayed
healing were atenuated in completely re epithelialised 14 day
wounds, thus wound chronification was not atained in the dia
betic skin humanised mouse model. Limiting factors, such as, the
acute toxicity exerted by STZ and the use of cels from healthy
donors employed for assembling the bioengineered human skin
equivalents, could explain the lack of chronicity.
As diabetic ulcers respond poorly to conventional treatments
(12), new approaches are needed. Advanced cel therapies using
healthy alogenic fibroblasts emerge as atractive strategies to over
come the senescence of fibroblasts present in chronic wound beds
(61,62). Intracelular signaling activated via cytokines, growth fac
tors and proteolytic enzymes secreted by alogenic healthy fibro
blasts seems to stimulate the recipient’s own wound bed derived
skin cels and therefore crucial processes frequently altered in
diabetic wounds, such as re epithelialisation and angiogenesis, are
activated (16 18). In addition, human fibroblasts are an easy to
handle, accessible cel source with acceptable cel yields obtained
from a relatively smal skin biopsy. These properties, together with
their low immunogenicity (63,64) make fibroblasts a suitable tar
get in tissue engineering for the treatment of chronic wounds of
diferent aetiology (65).
Furthermore, the use of fibrin, unlike other biomaterials such
as colagen, preserves the viability and functionality of epidermal
stem cels (29,30,32,66,67), because it is a reservoir of cytokines,
cloting, cel adhesion and growth factors. Plasma derived fibrin,
unlike commercial purified fibrinogen preparations, contains addi
tional factors such as fibronectin or thrombospondin that may
contribute to keratinocyte adherence and survival (39,68). More
over, fibrin provides a suitable three dimensional scafold to pro
mote migration, proliferation and diferentiation of the cels in
the wound bed (69).
In the present work, the skin humanised mouse model has been
exploited as an ideal preclinical platform to evaluate the efective
ness of fibroblast containing fibrin based dermal scafolds on
wound healing in a diabetic context. After 7 days of treatment, a
noteworthy enhancement of wound closure was achieved in dia
betic wounds, showing re epithelialisation rates comparable to
untreated control wounds. Interestingly, treatment with bioengi
neered dermis improved diabetic wounds by promoting wound
bed maturation. As these improvements were not achieved when
fibroblasts were not included in the fibrin matrix and these cels
are a wel known source of soluble mediators, we suggest
fibroblasts induced maturation of diabetic wounds in terms of
colagen deposition and wound bed vascularisation. Consequently,
the granulation tissue of improved quality would provide a suit
able matrix for keratinocyte migration, explaining the diferences
observed in wound closure after treatment.
Clinical benefits of tissue engineered products have been exten
sively demonstrated (19), although their use is considerably lim
ited due to the scarce availability and high cost associated with its
manufacture and development (70). In this context, the self made,
non commercial, bioengineered dermal seting we report herein
appears to be an atractive therapeutic alternative for diabetic
wounds not only in terms of efficacy, but also because of the sub
stantial cost savings.
In conclusion, the proposed model of delayed wound healing
emerges as a suitable preclinical tool to evaluate clinicaly mean
ingful innovative therapeutic approaches in the field of dermatol
ogy and also to provide a beter understanding of the biological
mechanisms involved in wound healing improvement after a treat
ment. Furthermore, we have demonstrated that bioengineered
fibroblast containing dermal substitutes are a powerful and trust
worthy tool for the treatment of diabetic wounds in a preclinical
context. The bioengineered dermis may represent a realistic, effi
cient and inexpensive strategy to overcome the granulation tissue
defects frequently associated not only with diabetic wounds but
also with ulcers of diferent aetiology.
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